Allspring Global Investments Holdings LLC Has $821,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Allspring Global Investments Holdings LLC boosted its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 27.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,276 shares of the company’s stock after acquiring an additional 20,916 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Voyager Therapeutics were worth $821,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in Voyager Therapeutics during the fourth quarter worth $43,000. Ritholtz Wealth Management increased its stake in shares of Voyager Therapeutics by 11.8% in the fourth quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after buying an additional 2,089 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at $25,000. Alps Advisors Inc. acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at $294,000. Finally, Armistice Capital LLC increased its stake in shares of Voyager Therapeutics by 15.3% in the third quarter. Armistice Capital LLC now owns 4,178,000 shares of the company’s stock valued at $32,380,000 after buying an additional 554,000 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Trading Down 1.0 %

Shares of VYGR opened at $7.57 on Thursday. Voyager Therapeutics, Inc. has a 1 year low of $6.06 and a 1 year high of $14.34. The stock has a market cap of $411.06 million, a P/E ratio of 2.45 and a beta of 0.96. The stock’s 50-day moving average price is $8.80 and its two-hundred day moving average price is $7.97.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The firm had revenue of $90.06 million for the quarter, compared to analysts’ expectations of $4.95 million. As a group, equities analysts forecast that Voyager Therapeutics, Inc. will post -1.64 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VYGR. Guggenheim began coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $22.00 target price for the company. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $9.00 to $14.00 in a research note on Tuesday, January 2nd. HC Wainwright assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price objective for the company. Citigroup assumed coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.